Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biocon Claims Edge For Adalimumab In US

Cites Encouraging Payer Discussions Over Humira Biosimilar

Executive Summary

Biocon, which is set to close its deal with Viatris shortly, says it is in a “very good position” to vie for a share of the adalimumab biosimilar pie in the US and has had encouraging preliminary discussions with payers.

You may also be interested in...



Biocon Closes $3bn Deal For Viatris Biosimilars

Biocon has achieved a milestone after its Biocon Biologics subsidiary closed its $3bn deal to acquire the biosimilars business of longtime partner Viatris, in what management described as a “historic inflection point” for the Indian player.

Biocon Meets $650m Equity Infusion In Biocon Biologics To Fund Viatris Buy

Biocon Biologics is continuing to rack up the capital needed to close its multi-billion deal for Viatris’ global biosimilars business, with two quick equity investments from parent Biocon Limited as stipulated under its acquisition agreement.

Alvotech Reiterates Meeting US Humira Biosimilar Launch Date

Recently public Alvotech had much to share as part of its nine-month financial report, including updates on adalimumab in the US and the process to begin biosimilar golimumab trials.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB152314

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel